Brokerages expect Cara Therapeutics Inc (NASDAQ:CARA) to announce sales of $5.58 million for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Cara Therapeutics’ earnings. The highest sales estimate is $6.50 million and the lowest is $5.00 million. Cara Therapeutics reported sales of $5.53 million in the same quarter last year, which indicates a positive year over year growth rate of 0.9%. The firm is expected to issue its next earnings report on Tuesday, March 10th.
On average, analysts expect that Cara Therapeutics will report full-year sales of $20.91 million for the current financial year, with estimates ranging from $20.20 million to $21.88 million. For the next year, analysts forecast that the company will report sales of $20.94 million, with estimates ranging from $19.33 million to $23.96 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that follow Cara Therapeutics.
Cara Therapeutics (NASDAQ:CARA) last announced its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The company had revenue of $5.79 million for the quarter, compared to the consensus estimate of $5.56 million. Cara Therapeutics had a negative return on equity of 70.35% and a negative net margin of 470.70%.
NASDAQ:CARA traded up $1.39 during trading hours on Wednesday, hitting $25.94. The company had a trading volume of 577,434 shares, compared to its average volume of 698,894. The company has a market capitalization of $1.04 billion, a PE ratio of -12.59 and a beta of 2.23. The stock has a 50-day moving average price of $20.65 and a 200 day moving average price of $21.42. Cara Therapeutics has a 52 week low of $12.19 and a 52 week high of $27.55. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.21 and a quick ratio of 4.21.
In related news, CEO Derek T. Chalmers sold 5,000 shares of the stock in a transaction on Friday, November 1st. The stock was sold at an average price of $20.79, for a total transaction of $103,950.00. Following the sale, the chief executive officer now owns 928,468 shares in the company, valued at approximately $19,302,849.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeffrey L. Ives sold 2,500 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $23.31, for a total value of $58,275.00. Following the sale, the director now owns 8,500 shares in the company, valued at approximately $198,135. The disclosure for this sale can be found here. Insiders have sold a total of 63,500 shares of company stock valued at $1,325,470 over the last quarter. Corporate insiders own 5.80% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its stake in shares of Cara Therapeutics by 3.6% during the second quarter. BlackRock Inc. now owns 2,864,551 shares of the biopharmaceutical company’s stock valued at $61,587,000 after buying an additional 98,241 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Cara Therapeutics by 10.5% in the second quarter. Price T Rowe Associates Inc. MD now owns 2,800,339 shares of the biopharmaceutical company’s stock worth $60,207,000 after acquiring an additional 266,749 shares during the last quarter. First Manhattan Co. boosted its stake in shares of Cara Therapeutics by 97.5% in the second quarter. First Manhattan Co. now owns 1,938,188 shares of the biopharmaceutical company’s stock worth $41,671,000 after acquiring an additional 956,968 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Cara Therapeutics by 0.8% in the second quarter. Vanguard Group Inc. now owns 1,779,452 shares of the biopharmaceutical company’s stock worth $38,258,000 after acquiring an additional 13,417 shares during the last quarter. Finally, ETF Managers Group LLC acquired a new stake in shares of Cara Therapeutics in the second quarter worth approximately $20,490,000. Institutional investors own 76.08% of the company’s stock.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
Further Reading: Hedge Funds – Risk or Reward?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.